Core Insights - Kane Biotech Inc. is presenting clinical data on wound healing at the SAWC Fall conference, showcasing the effectiveness of their revyve Antimicrobial Wound Gel in treating complex wounds over two years old [1][4]. Group 1: Clinical Data Presentation - The first presentation discusses the clinical use of revyve Antimicrobial Wound Gel on a two-year-old non-healing Stage 4 sacral ulcer, resulting in pain reduction from 10/10 to 0 and a decrease in wound size over three weeks [2]. - The second presentation highlights the use of revyve Antimicrobial Wound Gel combined with vibrational debridement on a non-healing venous leg ulcer, achieving a 60% reduction in wound size over eight weeks and pain levels decreasing from 5/10 to 0 [3]. Group 2: Product Information - Kane Biotech's revyve Antimicrobial Wound Gel and Wound Gel Spray have received FDA 510(k) clearance and will be exhibited at the conference, with the Interim CEO meeting potential US distributors [4][6]. - The revyve products are designed to disrupt biofilms and improve healing outcomes, addressing antibiotic resistance in wounds, and are also approved by Health Canada [7].

Company Overview - Kane Biotech Inc. is focused on developing innovative wound care treatments that target biofilms, which are significant contributors to antibiotic resistance in wounds [3] - The company's product, revyve™, is designed to address both biofilms and wound bacteria, aiming to improve healing outcomes [3] Event Participation - Dr. Robert Huizinga, the Interim CEO of Kane Biotech, will present at the Advanced Wound Care Summit USA from July 15-17, 2025, in Boston, MA [1][2] - The presentation will be accessible on Kane's website starting July 16, 2025 [2] Industry Context - The Advanced Wound Care Summit USA serves as a platform for industry stakeholders, including innovators, payers, regulators, and multinational leaders, to collaborate on advancing wound care therapies [2]